Robert W. Baird Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price upped by Robert W. Baird from $52.00 to $62.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the stock. CRNX has been the topic of several other research reports. Oppenheimer boosted their price target on […]
More Stories
bioMérieux S.A. (OTCMKTS:BMXMF) Short Interest Update
bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) was the target of a significant drop in short interest during the month...
Short Interest in Camden National Co. (NASDAQ:CAC) Expands By 31.5%
Camden National Co. (NASDAQ:CAC – Get Free Report) was the target of a significant increase in short interest during the...
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI) Short Interest Up 48.8% in September
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI – Get Free Report) saw a large growth in short interest...
Stronghold Digital Mining, Inc. (NASDAQ:SDIG) Short Interest Update
Stronghold Digital Mining, Inc. (NASDAQ:SDIG – Get Free Report) was the recipient of a significant decrease in short interest in...
Otsuka Holdings Co., Ltd. (OTCMKTS:OTSKY) Sees Large Increase in Short Interest
Otsuka Holdings Co., Ltd. (OTCMKTS:OTSKY – Get Free Report) saw a significant growth in short interest in September. As of...
BTCS Inc. (NASDAQ:BTCS) Short Interest Update
BTCS Inc. (NASDAQ:BTCS – Get Free Report) was the target of a large decline in short interest in September. As...